175 results
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
Stock.
This discussion is for informational purposes only and is not tax advice. You should consult your own independent tax advisor concerning … -U.S. holder’s holding period for the Common Stock is longer than one year. A Non-U.S. holder should consult its own independent tax advisors
DEF 14C
gz8e 01lksf
29 Jan 24
Information statement
8:00am
PRE 14C
da5 dgfuh9ej
17 Jan 24
Preliminary information
5:05pm
8-K
EX-4.2
99i6 zhizjcb0
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
ra4qh89mq40w8f5q2da
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
1htlms0v7z5vwk
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
jv49q nxi2
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.1
d9mmlss4
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
pdga94vl tqc9
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.3
9p5y9vu44r
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
3hn0 1v5zmfgabwi
2 Nov 23
Prospectus supplement with pricing info
9:00am